Synthesis of new cocrystal solid form of fluconazole-fumaric acid
Abstract
Pharmaceutical cocrystals are multicomponent crystalline solids comprised of
an active pharmaceutical ingredient (API) and one or more co-formers
interacting through hydrogen bonding or other weak interactions like the π-stack
and van der Waals interactions. Fluconazole (FLZ) is a triazole antifungal drug
used in the treatment and prevention of superficial and systemic fungal
infections. It is also used to prevent and treat meningitis. Cocrystallization is an
alternative approach for enhancement of drug. It can be performed using neat
grinding, solvent assisted grinding, solvent evaporation, cooling evaporation
and slurry cocrystallization. In this work, a new cocrystal Fluconazol-Fumaric
acid monohydrate was synthesized via 1:1 stoichiometric amount of FLZ and
FUM at different conditions. The characterization of the synthesized cocrystals
was achieved using Raman spectroscopy, differential scanning calorimetry,
powder X-ray diffraction and single crystal X-ray diffraction. The results
obtained for the characterization of the samples showed some obvious
differences among the spectra, diffractograms and thermograms. The single
crystal X-ray diffraction analysis of the new structure shows a cocrystal where
the fluconazole molecules are attached to the fumaric acid and water molecules
respectively through hydrogen bonds, gave unique cell dimensions for an
assumed structure C17H18F2N6O6 with a space group of P21/n, a = 17.053(3) Å,
b = 5.5995(10), c=21.154(3), α = 90°, β=105.418(4)°, γ= 90°, V = 1947.3(6) Å3.
This work is the first to report a monohydrate cocrystal structure of fluconazole
and fumaric acid.